Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients

Mikocka‐Walus, Antonina; Turnbull, Deborah; Moulding, Nicole; Wilson, Ian G; Andrews, Jane M.; Holtmann, Gerald

doi:10.1002/ibd.20062

Cited by 305 publications

(370 citation statements)

References 41 publications

Supporting

Mentioning

328

Contrasting

Unclassified

Order By: Relevance

“…Our study also showed that the TNF-α rs1799724 C>T polymorphism increased the susceptibility to CD, which was in agreement with the results of 2 previous studies (Yang et al, 2006). Dysregulation of TNF-α is associated with the susceptibility to CD (Mikocka-Walus et al, 2007). It is well-known that TNF-α promoter polymorphisms affect gene expression (Mishra and Arankalle, 2011).…”

Section: Discussionsupporting

confidence: 92%

Association between TNF-αrs1799724 and rs1800629 polymorphisms and the risk of Crohn’s disease

Yq¹,

Sq²,

Gao³

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We investigated the associations between 2 major tumor necrosis factor-α (TNF-α) polymorphisms, rs1799724 C>T and rs1800629 G>A, and the susceptibility to Crohn's disease (CD) using a metaanalysis framework. The PubMed, EBSCO, Ovid, Wiley, Web of Science, WANFANG, and VIP databases (last updated search in October 2014) were comprehensively searched for relevant published studies. The studies retrieved from database searches were filtered based on inclusion and exclusion criteria, and the resultant data extracted from the selected studies were analyzed using the Comprehensive Meta-analysis 2.0 software. Eleven case-control studies, containing 2000 CD patients and 3499 healthy controls, were identified as relevant to this meta-analysis. Data extracted from these 11 studies were analyzed to understand the role of the 2 TNF-α polymorphisms in CD. We found that the TNF-α rs1799724 C>T (2015) polymorphism increased the susceptibility to CD (allele model: OR = 1.293, 95%CI = 1.090-1.534, P = 0.003; dominant model: OR = 1.258, 95%CI = 1.031-1.534, P = 0.024). In contrast, we found no significant association between the TNF-α rs1800629 G>A polymorphism and CD susceptibility (allele model: OR = 1.005, 95%CI = 0.864-1.170, P = 0.945; dominant model: OR = 0.962, 95%CI = 0.809-1.145, P = 0.667). This meta-analysis showed that the TNF-α rs1799724 C>T polymorphism is associated with CD susceptibility, while the TNF-α rs1800629 G>A polymorphism appeared to have no correlation with the susceptibility to CD.

show abstract

Section: Discussionsupporting

confidence: 92%

Association between TNF-αrs1799724 and rs1800629 polymorphisms and the risk of Crohn’s disease

Yq¹,

Sq²,

Gao³

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…A recent systematic review found that anxiety was present in 19% of IBD patients vs. 9.6% of the background population and depression was found in 21.2 with IBD vs. 13.4% in non-IBD controls. Th ere was just as much depression in those patients with inactive disease as measured by the Hospital Anxiety and Depression Scale as those with active disease ( 103 ). Th e impact of depression was measured in patients receiving infl iximab therapy for their active CD.…”

Section: Summary Of Evidencementioning

confidence: 99%

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

Farraye

Melmed

Lichtenstein

et al. 2017

American Journal of Gastroenterology

403

421

View full text Add to dashboard Cite

Recent data suggest that infl ammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy. In particular, documentation of up to date vaccinations are crucial as IBD patients are often treated with long-term immune-suppressive therapies and may be at increased risk for infections, many of which are preventable with vaccinations. Health maintenance issues addressed in this guideline include identifi cation, safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer as well as identifi cation of depression and anxiety and smoking cessation. To accomplish these health maintenance goals, coordination between the primary care provider, gastroenterology team and other specialists is necessary. of evidence, we entered data from the papers of highest evidence into the GRADE program (accessible at http://www.gradepro.org ). Th e recommendation statements from this guideline are shown in Table 1 . Summary statements, when listed, are designed to be descriptive in nature without associated evidence-based ratings. VACCINATIONSRecent data suggest that IBD patients do not receive preventive services at the same rate as general medical patients ( 2 ). Members of the gastroenterology team are oft en the only clinicians that a patient with IBD will see. As such, it is incumbent upon gastroenterologists to take a proactive role in the health care needs of their IBD patients ( 3-5 ). It is crucial to clarify with the patient the limits of the specialist's responsibilities and delegate routine health care issues to the primary care clinician. It is equally important to educate the primary care clinician to the unique health maintenance needs of the IBD patient, especially those on immunomodulators and biologic agents. Although it appears that both primary care clinicians and gastroenterologists are hesitant to take ownership of vaccinations ( 6-8 ), it is reasonable ( 9 ) that vaccination recommendations be the responsibility of the treating gastroenterologist, but the actual delivery/administration of these vaccines may be a shared responsibility ( 10-13 ). Communicating specifi c recommendations to the primary care team in a concise fashion are needed. Consider empowering the patient by giving written recommendations to bring to their primary care physician. Clinicians sharing an electronic medical record should use this platform to send recommendations to the referring clinician.Patients with IBD are oft en treated with long-term immunesuppressive therapies and may t...

show abstract

“…CD can change quality of life, especially during flares, and may cause major changes in the physical, emotional and social lives of patients. CD has been associated with symptoms of anxiety and depression (10)(11)(12) . There is evidence that the continuous psychological suffering can exacerbate disease activity and increase the risk of a flare (13)(14)(15) .…”

Section: Introductionmentioning

confidence: 99%

Symptoms of Anxiety and Depression, and Quality of Life of Patients With Crohn’s Disease

Tomazoni

Benvegnú

2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Crohn's disease is an idiopathic chronic inflammatory disease. It is classified as an inflammatory bowel disease. Crohn's disease can change patient quality of life, especially during flares. Crohn's disease has been associated with symptoms of anxiety and depression, because the clinical symptoms have a high impact on quality of life. Objective -To investigate the prevalence of symptoms of anxiety and depression in Brazilian patients diagnosed with Crohn's disease, as well as their quality of life. Methods -A total of 110 Brazilian patients aged 21-59 years, both genders, with Crohn's disease were included. The data were collected through questionnaires. The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depression symptoms. Quality of life was evaluated using the Inflammatory Bowel Disease Questionnaire. Data were analyzed by ANOVA, followed by the Duncan post-hoc test and the multiple linear regression test. Results -Of the total, 61.7% of participants reported symptoms of anxiety or depression or both. Regarding quality of life, the majority (43.6%) were classified as "regular" and the minority (3.6%) as "excellent". Multiple linear regression showed that worse quality of life correlated with greater presence of anxiety and depression symptoms (<0.001).Conclusion -Crohn's disease has considerable impact on quality of life and contributes to the appearance of anxiety and/or depression symptoms. HEADINGS -Crohn disease. Quality of life. Anxiety. Depression.

show abstract

Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients

Cited by 305 publications

References 41 publications

Association between TNF-αrs1799724 and rs1800629 polymorphisms and the risk of Crohn’s disease

Association between TNF-αrs1799724 and rs1800629 polymorphisms and the risk of Crohn’s disease

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

Symptoms of Anxiety and Depression, and Quality of Life of Patients With Crohn’s Disease

Contact Info

Product

Resources

About